A risk-benefit assessment of iron-chelation therapy

Drug Safety

Volumn 17, Issue 6, 1997, Pages 407-421

  Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; FREE RADICAL; IRON;

AGRANULOCYTOSIS; ARTHRITIS; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MALFORMATION; CARDIOTOXICITY; CELL METABOLISM; CHELATION THERAPY; CLINICAL TRIAL; DRUG EFFICACY; EYE TOXICITY; FEVER; GROWTH RETARDATION; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; LIFE EXPECTANCY; LIVER LEVEL; MYALGIA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY EXCRETION;

EID: 0031457203     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717060-00006     Document Type: Review

References (102)

1. Gordeuk VR, Bacon BR, Brittenham GM. Iron overload, causes and consequences. Ann Rev Nutr 1987; 7: 485-508
2. Zurlo MG, Stefaano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; II: 27-30
3. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331 (9): 567-73
4. Olivieri N, Brittenham G. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89 (3): 739-61
5. Cohen A, Martin M, Schwartz E. Depletion of excessive iron stores with desferrioxamine. Br J Haematol 1984; 58: 369-73
6. Aldouri MA, Wonke B, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 1987; 40: 1353-9
7. Olivieri NF. Randomised trial of deferiprone and DFO in thalassaemia major [abstract 2593]. Blood 1996; 88 (10 Suppl. 1): 651a
8. Crichton RR, Roman F, Roland F. Iron mobilisation from ferritin by chelating agents. J Inorg Biochem 1980; 13: 305-16
9. Freeman AP, Giles RW, Berdoukas V, et al. Sustained normalisation of cardiac function by chelation therapy in thalassaemia major. Clin Lab Haematol 1989; 11 (4): 299-307
10. Marcus RE, Davies SC, Bantock HM, et al. Desferrioxamine to improve cardiac function in iron overloaded patients with thalassaemia major. Lancet: 1984; I: 392-3
11. Gutteridge JMC, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin Haematol 1989; 2: 195-256
12. Hershko C, Graham G, Bates GW, et al. Non-specific serum iron in thalassaemia: an abnormal serum fraction of potential toxicity. Br J Haematol 1978; 40: 255-63
13. Porter JB, Abeysinghe RD, Marshall L, et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. Blood 1996; 88 (2): 705-14
14. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood 1977; 50: 433-9
15. Pollack S, Weaver J, Zhan H. Intracellular iron. Adv Exp Med Biol 1994; 356: 165-71
16. Mulligan MM, Althus B, Linder MC. Non-ferritin, non-heme iron pools in rat tissues. Int J Biochem 1986; 18: 791-8
17. Hider RC, Choudhury R, Rai BL, et al. Design of orally active iron chelators. Acta Haematol 1996; 95: 6-12
18. Hider RC, Porter JB, Singh S. The design of therapeutically useful iron chelators. In: Bergeron RJ, Brittenham G, editors. The development of iron chelators for clinical use. Boca Raton. FI.: CRC Press, 1994: 353-71
19. Aheysinghe RD, Roberts PJ, Cooper CE. et al. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J Biol Chem 1996; 271: 7965-72
20. Cooper C, Lynagh G, Hider RC, et al. Inhibition of ribonucleotide reductase by intracellular iron chelation as monitored by electron paramagnetic resonance. J Biol Chem 1996; 271 (34): 20291-9
21. Hoycs KP, Hider RC, Porter JB. Cell cycle synchronisation and growth inhibition by 3-hydroxypyridinone iron chelators in leukaemia cell lines. Cancer Res 1992; 52 (17): 4591-9
22. Porter JB, Lynagh GR, Hider RC. Thymocyte apoptosis: a rapid model for comparative screening of iron chelators: implications for treatment of iron overload in thalassaemia. In: Beuzard Y, Lubin B, Rosa J, editors. Sickle cell disease and thalassaemia: new trends in therapy. Montrouge, France: John Libby Eurotext, 1995; 234: 371-2
23. Lee P, Mohammed N, Abeysinghe RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients. Drug Metab Dispos 1993; 21 (4): 640-4
24. Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol 1990; 48: 255-61
25. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91 (1): 224-9
26. Al-Refaic FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator (L1) in patients with iron overload. Br J Haematol 1995; 89: 403-8
27. Pippard MJ, Johnson DK, Callender ST, et al. Ferrioxamine excretion in iron loaded man. Blood 1982; 60: 288-94
28. Olivieri NF, Koren G, Herman C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron loaded patients. Lancet 1990; 336: 1275-9
29. Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profile in man and rat of 1,2-dimethyl and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 1992; 20 (2): 256-61
30. Porter JB, Hider RC, Huehns ER. The development of iron-chelating drugs. Baillieres Clin Haematol 1989; 2: 257-92
31. Singh S, Hider RC, Porter JB. Separation and identification of desferrioxamine and its iron chelating metabolites by highperformance liquid chromalography and fast atom bombardment mass spectrometry. Anal Biochem 1990; 187: 1-8
32. Hershko C, Cook JD, Finch CA. Storage iron kinetics. III: Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med 1973; 81: 876-86
33. Hershko C, Rachmilewilz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br J Haematol 1979; 42: 125-32
34. Hershko C, Grady RW, Cerami RW. Mechanism of iron chelalion in the hypertransfused rat: definition of two alternative pathways of iron mobilisation. J Lab Clin Med 1978; 92: 144-51
35. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol 1989; 2 (2): 323-43
36. Saito K, Nishisato T, Grasso JA, et al. Interaction of transferrin with iron loaded rat peritoneal macrophages. Br J Haematol 1986; 62: 275-86
37. Andriani M, Nordio M, Saporiti E. Estimation of statistical moments for desferrioxamine and its iron and aluminium chelates: contribution to optimisation of therapy in uraemic patients. Nephron 1996; 72: 218-24
38. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. BMJ 1962; 2: 1577-80
39. Barry M, Flynn DM, Letsky EA, et al. Long term chelation therapy in thalassaemia: effect on liver iron concentration. liver histology and clinical progress. BMJ 1974; 2: 16-20
40. Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 1976; 294: 1421-3
41. Pippard MJ, Callender ST, Weatherall DJ. Intensive iron-chelation with desterrioxamine in iron-loading anaemias. Clin Sci Molecul Med 1978; 54: 99-106
42. Nienhuis A. Vitamin C and Iron. N Engl J Med 1981; 304 (3): 170-1
43. Pippard MJ, Letsky EA, Callender ST, et al. Prevention of iron loading in transfusion-dependent thalassemia. Lancet 1978; 1: 1179-81
44. Modell CB, Beck J. Long term desferrioxamine therapy in thalassaemia. Ann NY Acad Sci 1974; 232: 201-10
45. Olivieri NF. Long term follow up of body iron in patients with thalassaemia major during therapy with the orally active iron chelator deferiprone (L1) [abstract 1229]. Blood 1996; 10: 310a
46. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in β thalassaemia with the oral chelator 1,2,dimethyl-3-hydroxypyridin-4-one. BMJ 1987; 295: 1509-12
47. Olivieri NF, Cameron RG, Brittenham GM. Exacerbation of hepatic fibrosis in patients with thalassemia major receiving the orally active chelator deferiprone (L1). Proceedings of the International Conference on HIV and Iron; 1997 Mar 14-15: Brugge, poster PB2
48. Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. BMJ 1982; 284: 1081-4
49. Gabutti V, Piga A. Results of long term chelation therapy. Acta Haematol 1996; 95: 26-36
50. Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; II: 181-4
51. De Virgillis S, Congia M, Frau F, et al. Desferrioxamine-induced growth retardation in patients with thalassaemia major. J Paediatr 1988; 4: 661-9
52. Piga A, Luzzatto L, Capalbo P, et al. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. Eur J Haematol 1988; 40: 380-1
53. Araujo A, Kosaryan M, MacDowell A, et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol 1996; 93 (4): 835-7
54. Porter JB, Jaswon MS, Huehns ER. et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haemalol 1989; 73: 403-9
55. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily high dose intravenous chelation therapy. J Pediatr 1987; 115: 151-5
56. Porter JB, Faherty AM. 12 years experience of intravenous desferrioxamine using indwelling intravenous devices in thalassaemia [abstract 334]. Br J Haematol 1996; 93 Suppl. I: 86
57. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130 (1): 86-8
58. Jensen P, Heickendorff L, Pedersen B, et al. The effect of iron chelyation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94 (2): 288-99
59. Alberti P, Piga A, Porter J, et al. Preliminary results of single s.c. bolus injections of the new depot formulation of desferrioxamine in thalassemia major patients [abstract]. Proceedings of 8th International Conference on Oral Iron Chelation. 1997 Sep 19-21: Corfu, 48
60. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331 (9): 574-8
61. Porter JB, Huchns ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989; 2: 459-74
62. Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Haematol 1979; 11: 267-312
63. Agarwal MB, Gupte SS, Viswanathan D, et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia. Br J Haematol 1992; 82: 460-6
64. Walker JA, Sherman RA, Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. Am J Kid Dis 1985; 6: 254-6
65. Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial [letter]. Lancet 1989; II: 457
66. Olivieri NF, Buncie JR, Chew E, et al. Visual and atiditory neurotoxicity in patients receiving subcutancous desferrioxamine infusions. N Engl J Med 1986; 314 (14): 869-73
67. Chiodo A, Alberti P, Sher G, et al. Desferrioxamine ototoxicity in an adult transfusion dependent population. J Otolarangol 1997; 26 (2): 116-22
68. Arden GB, Wonke B, Kennedy C, et al. Ocular changes in patients undergoing long term desferrioxamine treatment. Br J Opthalmol 1984; 68: 873-7
69. Miller KB, Rosenwasser LJ, Bessette JM, et al. Rapid desensitisation for desferrioxamine anaphylactic reaction [letter]. Lancet 1981; I: 1059
70. Freedman MH, Grisaru D, Olivieri NF, et al. Pulmonary syndrome in patients with thalassaemia receiving intravenous desferrioxamine infusions. Am J Dis Child 1990; 144:565-569
71. Koren G, Kochavi Atiya Y, Bentur Y, et al. The effects of sub-cutancous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991; 54 (5): 371-5
72. Mehta J, Singhal S, Revanker R, et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 [letter]. Lancet 1991; 337: 298
73. De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassaemia major patients with severe one lesions due to desferrioxamine. Eur J Pediatr 1996; 155: 368-72
74. Robins-Browne RM, Prpie JK. Desferrioxamine and systemic yersiniosis [letter]. Lancet 1983; II: 1372
75. Gallant R, Freedman MH, Vellend H, et al. Yersinia sepsis in patients with iron overload treated with desferrioxamine [letter]. N Engl J Med 1986; 314: 1643
76. Kouides PA, Slapak CA, Rosenwasser LJ, et al. Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy. Br J Haematol 1988; 70: 382-4
77. Boelaert JR, Verauwe PL, Vandepitte JM. Mucormycosis infoctions in dialysis patients. Ann Intern Med 1987 107 (5): 782-3
78. Bosquet J, Navarro M, Robert G, et al. Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet 1983; II: 859-60
79. Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with desferrioxamine therapy. Am J Dis Child 1990; 143 (9): 1077-80
80. Tenenhein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339: 699-701
81. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985; 56: 345-55
82. Dickerhoff R. Acute aphasia and loss of vision with desferrioxamine overdose. J Pediatr Hematol Oncol 1987; 9: 287-8
83. Lange R, Lameijer W, Roozendaal KL, et al. Pharmaceutical analysis and pharmacokinetics of the oral iron chelator 1,2-dimethyl-3-hydroxypyridi-4-one [abstract]. Proceedings 4th International Conference on Oral Chelation: 1993 Mar 26-29: Limasol, Cyprus, 11
84. Pippard MJ, Pattanapanyssat K, Tiperkae J, et al. Metabolism of the iron chelates of desferrioxamine and hydroxypyridinones in the rat [abstract]. Proceedings of the European Iron Club: 1989 Aug 28-31: Budapest, 55
85. Dobbin PS, Hider RC, Hall AD, et al. Synthesis, physicochemical proerties and biological evaluation of N-substituted-2-alkyl-3-hydroxy-4(iH)-pyridinones. J Med Chem 1993; 36 (17): 2448-58
86. Cragg L, Hebbel RP, Solovey A, et al. The iron chelator L1 potentiatesiron-mediated oxidative DNA damage [abstract 2573]. Blood 1996; 88 (10 Suppl. I): 646a
87. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and doseresponse studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83 (8): 2329-33
88. Kontoghiorghes GJ, Sheppard L, Barr J, et al. Iron balance studies with the oral chelator 1,2,dimethyl-3-hydroxypyridin-4-one [abstract]. Br J Haematol 1988; 69: 129
89. Stefanini S, Chiancone E, Cavallo S, et al. The interaction of hydroxypyridinones with human serum transferrin and ovotransferrin. J Inorg Biochem 1991; 44 (1): 27-37
90. Kontoghiorghes GJ, Aldouri MA, Sheppard L, et al. 1,2-Dimethyl-3-hydroxypyrid-4-one. an orally active chelator for treatment of iron overload. Lancet 1987; I: 1294-5
91. Al Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one (L1) in thalassemia major. Blood 1992; 80: 593-9
92. Olivieri NF, Brittenham GM, Mutsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332 (14): 918-22
93. Hoffbrand AV, Wonke B, Al-Refaie F, et al. Over 3 year follow up of 56 transfusion dependent patients receiving oral iron chelation [abstract 2592]. Blood 1996; 88 (10 Suppl 1): 651a
94. Callea F, Faa G, Sciot R, Liver histology in thalassemia patients receiving deferiprone [abstract]. 8th International Conference on oral iron chelation: 1997 Sep 19-21: Corfu. 59
95. Brittenham GM, Development of iron-chelating agents for clinical use. Blood 1992; 80: 569-74
96. Porter JB, Hoyes KP, Abeysinghe RD, et al. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and non-overloaded mice. Blood 1991; 79: 2727-34
97. Porter JB, Hoyes KP, Abeysinghe R, et al. Animal toxicology of iron chelator L1 [letter]. Lancet 1999; II: 156.
98. Berdoukas V, Bentley P, Frost H, et al. Toxicity of oral chelator L1 [letter]. Lancet 1993; 341: 1088
99. Carthew P, Dorman BM, Edwards RE, et al. A unique rodent model for both cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 1993; 69: 217-22
100. Hoffbrand AV, Prospects for oral iron chelation. J Lab Clin Med 1994; 21: 86-92
101. Cohen A. A multicenter safety trial of the oral iron chelator deferiprone [abstract No. 26]. 7th Cooleys Anaemia Symposium: 1997 May 30-Jun 2: Cambridge MA, USA
102. Mehta J, Chablani A, Reporter R, et al. Autoantibodies in thalassaemia major: relationship with oral iron chelator L1. J Assoc Physicians India 1993; 41 (6): 339-41